Key Takeaways
- The RapidLink pivotal investigational device exemption (IDE) study has enrolled its first patient in the USA and Europe to evaluate the safety and effectiveness of the RapidLink device for repairing or replacing supra-aortic vessels.
- The study aims to collect data on patients undergoing open surgical repair of aortic disease involving the thoracic aorta and will include up to 30 centers in the USA and Europe.
- The RapidLink device is designed to simplify the hybrid approach to aortic arch repair, reducing procedural complexity, operative time, and patient risk.
- The device is intended for use in all three supra-aortic vessels for repair or replacement and will be followed for a minimum of two years post-procedure.
- The study’s global principal investigator, Malakh Shrestha, believes that the RapidLink device provides a transformative solution for complex aortic arch procedures.
Introduction to the RapidLink Deployment Device
The RapidLink deployment device, developed by Terumo Aortic, has reached a significant milestone with the enrollment of the first patient in the RapidLink pivotal investigational device exemption (IDE) study in the USA and Europe. This study is designed to evaluate the safety and effectiveness of the RapidLink device for the repair or replacement of supra-aortic vessels during open surgical repair of aortic disease involving the thoracic aorta. The device is intended to simplify the hybrid approach to aortic arch repair, which can be a complex and technically demanding procedure.
Study Design and Objectives
The study will collect information on patients who are already undergoing surgery to repair their aorta and will have the RapidLink device implanted into one or more of the aortic arch vessels. The study will include up to 30 centers in the USA and Europe, with Terumo Aortic anticipating that up to 150 patients will be enrolled across the two study arms: elective and emergent. The device is designed to be used in all three supra-aortic vessels for repair or replacement, and patients will be followed for a minimum of two years post-procedure. The study’s primary objective is to evaluate the safety and effectiveness of the RapidLink device in this patient population.
Benefits of the RapidLink Device
According to Terumo Aortic, the RapidLink device provides an "intuitive" deployment system that integrates into existing surgical workflows, reducing the number of procedural steps and enabling faster and more precise graft placement. This can lead to a reduction in procedural complexity, operative time, and patient risk. The device is designed to simplify the hybrid approach to aortic arch repair, which can be a challenging procedure for surgeons. By streamlining this approach, the RapidLink device is expected to allow more surgeons to treat complex aortic arch pathologies with confidence and consistency.
Global Principal Investigator’s Perspective
The global principal investigator of the study, Malakh Shrestha, commented on the significance of the RapidLink device, stating that it provides a "transformative solution for complex aortic arch procedures." Shrestha believes that the device simplifies the most technically demanding aspects of hybrid aortic arch repair, reducing procedural complexity, operative time, and patient risk. This perspective highlights the potential benefits of the RapidLink device in improving patient outcomes and simplifying the surgical procedure.
First Patient Enrollment and Future Directions
The first patient was enrolled in the study by Puja Kachroo at the Washington University Aortic Center in St. Louis, USA. This milestone marks the beginning of the study, which will provide valuable insights into the safety and effectiveness of the RapidLink device. As the study progresses, Terumo Aortic will continue to collect data on the device’s performance and safety, with the goal of obtaining regulatory approval for commercialization. The company advises that the RapidLink device is an investigational device and is limited by federal law to investigational use, emphasizing the need for further research and evaluation before it can be widely adopted.
Conclusion
In conclusion, the RapidLink deployment device has the potential to revolutionize the treatment of complex aortic arch pathologies by simplifying the hybrid approach to aortic arch repair. The enrollment of the first patient in the RapidLink pivotal IDE study marks an important milestone in the device’s development, and the study’s findings will provide valuable insights into the device’s safety and effectiveness. As the study progresses, Terumo Aortic will continue to work towards obtaining regulatory approval for commercialization, with the goal of making the RapidLink device available to surgeons and patients worldwide.